2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175763
    Z55660043 865271-09-6
    Z55660043 is a Regulator of G protein signaling-14 (RGS14) inhibitor with an IC50 of 2.3  μM. Z55660043 selectively and non-covalently inhibits RGS14 GTPase-accelerating protein (GAP) activity without measurable cytotoxicity. Z55660043 can be used for central nervous system and metabolic disorders research.
    Z55660043
  • HY-175784
    CB2R antagonist 4 1341021-90-6
    CB2R antagonist 4 is a selective CB2R antagonist/inverse agonist with a pKi of 6.54. CB2R antagonist 4 shows a ≥11-fold selectivity towards CB2R over CB1R and can be utilized in neurological research.
    CB2R antagonist 4
  • HY-175807
    ppGalNAc-T2-IN-1 1112431-86-3 98%
    ppGalNAc-T2-IN-1 is a polypeptide N-acetylgalactosaminyltransferase 2 (ppGalNAc-T2) inhibitor with an IC50 of 7.11 μM. ppGalNAc-T2-IN-1 is applicable for research on metabolic and neurodevelopmental disorders.
    ppGalNAc-T2-IN-1
  • HY-175816
    5-HT6R/FAAH modulator 1 98%
    5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pKi of 6.33 (5-HT6) and a pIC50 valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC50 = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD).
    5-HT6R/FAAH modulator 1
  • HY-175822
    5-HT2A inverse agonist-1 3028943-38-3
    5-HT2A inverse agonist-1 is a 5-HT2A receptor inverse agonist with a IC50 of 5.5 nM. 5-HT2A inverse agonist-1 shows minimal hERG inhibition. 5-HT2A inverse agonist-1 can be used for the research of neurological disease, such as Parkinson’s disease.
    5-HT2A inverse agonist-1
  • HY-175823
    1,4-Naphthoquinone-NH-C2-NH-Trolox 98%
    1,4-Naphthoquinone-NH-C2-NH-Trolox is a brain-penetrant Trolox (HY-101445)-vitamin K (HY-B2172) conjugate with neuroprotective activity. 1,4-Naphthoquinone-NH-C2-NH-Trolox can inhibit oxytosis, ferroptosis, ATP depletion and ROS production. 1,4-Naphthoquinone-NH-C2-NH-Trolox selective suppresses M1 markers expression. 1,4-Naphthoquinone-NH-C2-NH-Trolox can be used for the research of neurological disease, such as Alzheimer’s disease (AD).
    1,4-Naphthoquinone-NH-C2-NH-Trolox
  • HY-175824
    PSD-95/nNOS PPI-IN-1 98%
    PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (Ki = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke.
    PSD-95/nNOS PPI-IN-1
  • HY-175841
    Tau Protein Phosphorylation-IN-1 3075165-36-2
    Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that potently protects PC12 cells against Aβ25–35-induced cytotoxicity (EC50 = 1.93 μM), and can penetrate the blood-brain barrier (BBB).Tau Protein Phosphorylation-IN-1 reverses the hyperphosphorylation of tau, significantly inhibits the expression of certain immune-related cytotoxic factors, suppresses the MAPK and NF-κB signaling pathways, and significantly inhibits the expression of RAGE and the apoptosis factors Bax/Bcl-2, both in vitro and in vivo. Tau Protein Phosphorylation-IN-1 relieves nerve damage, and improves learning and memory in an Alzheimer’s disease (AD) mouse model. Tau Protein Phosphorylation-IN-1 can be used for AD research.
    Tau Protein Phosphorylation-IN-1
  • HY-175851
    A2AAR antagonist 5
    A2AAR antagonist 5 is a selective A2AAR antagonist. A2AAR antagonist 5 inhibits NECA-stimulated adenylyl cyclase activity in hA2AAR-expressing CHO cells with an IC50 value of 1863 nM. A2AAR antagonist 5 possesses strong free radical scavenging activity, with an EC50 value of 22.21 μM in the DPPH assay. A2AAR antagonist 5 exerts notable neuroprotective effects in in vitro cerebral ischemia models. A2AAR antagonist 5 can be used for the study of cerebral ischemia.
    A2AAR antagonist 5
  • HY-175856
    AChE-IN-95
    AChE-IN-95 (Compound 7) is a highly selective competitive acetylcholinesterase (AChE) inhibitor (IC50=17.87 μM, Ki=19.48 μM). AChE-IN-95 exhibits strong cytotoxicity against SH-SY5Y neuroblastoma cells. AChE-IN-95 is promising for research of Alzheimer’s disease and neurodegenerative disorders.
    AChE-IN-95
  • HY-175970
    MLS000099089 423735-70-0 98%
    MLS000099089 is a 12/15-lipoxygenase (12/15-LOX) inhibitor with IC50 values of 3.4 μM and 10 μM for human and mice 12/15-LOX, respectively. MLS000099089 displays higher selectivity for 12/15-LOX over 5-LOX and COX-2. MLS000099089 can be used for the study of stroke.
    MLS000099089
  • HY-175972
    CAI/II-IN-12 98%
    CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma.
    CAI/II-IN-12
  • HY-175973
    AChE/BChE-IN-30 98%
    AChE/BChE-IN-30 (Compound 3g) is a Cholinesterase dual-target competitive inhibitor. AChE/BChE-IN-30 can inhibit AChE and BChE with IC50 values of 0.338 and 2.087 μM and Ki values of 0.045 and 0.789 μM. AChE/BChE-IN-30 can be used for the research of neurological disease, such as Alzheimer's disease.
    AChE/BChE-IN-30
  • HY-176052
    PPO-allene 98%
    PPO-allene is a covalent botulinum neurotoxin (BoNT) light chain inhibitor (IC50: 20.9 μM). PPO-allene (0.3 mg/kg, i.v.) demonstrates an in vivo half-life of approximately 1.5 h in mice.
    PPO-allene
  • HY-176063
    TRPV1 antagonist 11 3084843-71-7 98%
    TRPV1 antagonist 11 (compound 2ac) is a potent TRPV1 antagonist with an IC50 of 29.3 nM. TRPV1 antagonist 11 is a potent μ-opioid receptor (MOR) agonist with a Ki of 60.3 nM. TRPV1 antagonist 11, a pyrimidine piperazine, exhibits pain relieving effects by antagonizing TRPV1 and stimulating MOR. TRPV1 antagonist 11 shows a potent, dose-dependent anti-nociceptive effect in a Formalin-induced pain model in mice.
    TRPV1 antagonist 11
  • HY-176065
    Nav1.2-IN-1 3084825-09-9 98%
    Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC50 value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode.
    Nav1.2-IN-1
  • HY-176101
    Deschloro W-19 hydrochloride
    Deschloro W-19 (hydrochloride) is an analytical reference standard with structural similarity to known analgesics.
    Deschloro W-19 hydrochloride
  • HY-176122
    VU6024945 98%
    VU6024945 is an orally active negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGlu5 NAM) with an IC50 value of 110 nM. VU6024945 can be used in the research of anti-anxiety, anti-depression and Parkinson's disease and other neurological diseases.
    VU6024945
  • HY-17612A
    Evenamide hydrochloride 1092977-06-4 98%
    Evenamide hydrochloride is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 μM) for the research of schizophrenia. Evenamide hydrochloride shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
    Evenamide hydrochloride
  • HY-176132
    BI 1181181 MZ 98%
    BI 1181181 MZ is a potent and selective BACE1 inhibitor. BI 1181181 MZ can be used in the research for Alzheimer’s disease.
    BI 1181181 MZ
Cat. No. Product Name / Synonyms Application Reactivity